180 related articles for article (PubMed ID: 29513759)
21. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
22. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
23. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
[TBL] [Abstract][Full Text] [Related]
24. IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.
Fang H; Reichard KK; Rabe KG; Hanson CA; Call TG; Ding W; Kenderian SS; Muchtar E; Schwager SM; Leis JF; Chanan-Khan AA; Slager SL; Braggio E; Smoley SA; Kay NE; Shanafelt TD; Van Dyke DL; Parikh SA
Am J Hematol; 2019 Mar; 94(3):338-345. PubMed ID: 30575108
[TBL] [Abstract][Full Text] [Related]
25. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
[TBL] [Abstract][Full Text] [Related]
26. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
Li Z; Li F; Yi S; Gu Z; Yu Z; Xu Y; Feng X; Liu W; Zou D; Qi J; Zhan F; Qiu L
BMC Cancer; 2015 Jul; 15():555. PubMed ID: 26219471
[TBL] [Abstract][Full Text] [Related]
27. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
Burger JA; Sivina M; Jain N; Kim E; Kadia T; Estrov Z; Nogueras-Gonzalez GM; Huang X; Jorgensen J; Li J; Cheng M; Clow F; Ohanian M; Andreeff M; Mathew T; Thompson P; Kantarjian H; O'Brien S; Wierda WG; Ferrajoli A; Keating MJ
Blood; 2019 Mar; 133(10):1011-1019. PubMed ID: 30530801
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic factors for chronic lymphocytic leukemia with typical and atypical immunophenotype].
Cao X; Xu W; Wu YJ; Qiao C; Liu Q; Fan L; Miao KR; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2009 Jul; 30(7):450-3. PubMed ID: 19954596
[TBL] [Abstract][Full Text] [Related]
29. Prognostic features and therapeutical approaches in B-cell chronic lymphocytic leukemia: an update.
Molica S; De Rossi G; Luciani M; Levato D
Haematologica; 1995; 80(2):176-93. PubMed ID: 7628755
[TBL] [Abstract][Full Text] [Related]
30. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
Lin KI; Tam CS; Keating MJ; Wierda WG; O'Brien S; Lerner S; Coombes KR; Schlette E; Ferrajoli A; Barron LL; Kipps TJ; Rassenti L; Faderl S; Kantarjian H; Abruzzo LV
Blood; 2009 Apr; 113(14):3168-71. PubMed ID: 19050308
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
[TBL] [Abstract][Full Text] [Related]
32. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
Kabadi SM; Near A; Wada K; Burudpakdee C
Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
[TBL] [Abstract][Full Text] [Related]
33. [Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prognostic factors].
Xu W; Shen QD; Yu H; Qiao C; Wu YJ; Liu Q; Zhu DX; Miao KR; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):8-12. PubMed ID: 19563027
[TBL] [Abstract][Full Text] [Related]
34. Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia.
Miao Y; Fan L; Wu YJ; Xia Y; Qiao C; Wang Y; Wang L; Hong M; Zhu HY; Xu W; Li JY
Oncotarget; 2016 Mar; 7(12):13551-62. PubMed ID: 26910908
[TBL] [Abstract][Full Text] [Related]
35. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
Strati P; Wierda W; Burger J; Ferrajoli A; Tam C; Lerner S; Keating MJ; O'Brien S
Cancer; 2013 Nov; 119(21):3805-11. PubMed ID: 23943357
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic significance of telomere length in patients with chronic lymphocytic leukemia].
Hou YQ; Xu W; Miao KR; Qiao C; Zhu HY; Zhu DX; Zhuang Y; Wu YJ; Wang JN; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):570-4. PubMed ID: 20561403
[TBL] [Abstract][Full Text] [Related]
37. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
[TBL] [Abstract][Full Text] [Related]
38. Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin-6 production.
Lagneaux L; Delforge A; Dorval C; Bron D; Stryckmans P
Blood; 1993 Oct; 82(8):2379-85. PubMed ID: 7691258
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B-CLL: implications for rituximab resistance in CLL.
Marquez ME; Hernández-Uzcátegui O; Cornejo A; Vargas P; Da Costa O
Br J Haematol; 2015 Apr; 169(2):211-8. PubMed ID: 25612644
[TBL] [Abstract][Full Text] [Related]
40. A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
Izutsu K; Kinoshita T; Takizawa J; Fukuhara S; Yamamoto G; Ohashi Y; Suzumiya J; Tobinai K
Jpn J Clin Oncol; 2021 Mar; 51(3):408-415. PubMed ID: 33244584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
